首页> Cancer research> Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells.

Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells.

导出原文传递

翻译打印收藏纠错

第一作者： Deepak,Mittal

第一单位： Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. School of Medicine, University of Queensland, Herston, Queensland, Australia.

作者： Deepak,Mittal ^[1] ; Franco,Caramia ^[2] ; Stefan,Michiels ^[3] ; Heikki,Joensuu ^[4] ; Pirkko-Liisa,Kellokumpu-Lehtinen ^[5] ; Christos,Sotiriou ^[6] ; Sherene,Loi ^[2] ; Mark J,Smyth ^[7]

作者单位： Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. School of Medicine, University of Queensland, Herston, Queensland, Australia. ^[1] Peter MacCallum Cancer Centre, University of Melbourne, East Melbourne, Victoria, Australia. ^[2] Service de Biostatistique et d'Epidemiologie, Gustave Roussy, Villejuif, France. INSERM U1018, CESP, Université Paris-Sud, Université Paris-Saclay, Villejuif, France. ^[3] Department of Oncology, Helsinki University Central Hospital and Helsinki University, Helsinki, Finland. ^[4] Department of Oncology, Tampere University Hospital and Tampere University, Tampere, Finland. ^[5] Breast Cancer Translational Research Laboratory, Université Libre de Bruxelles, Institut Jules Bordet, Brussels, Belgium. ^[6] Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. School of Medicine, University of Queensland, Herston, Queensland, Australia. Mark.Smyth@qimrberghofer.edu.au. ^[7]